List of Rasuvo drug patents

Rasuvo is owned by Medexus.

Rasuvo contains Methotrexate.

Rasuvo has a total of 1 drug patent out of which 0 drug patents have expired.

Rasuvo was authorised for market use on 10 July, 2014.

Rasuvo is available in solution;subcutaneous dosage forms.

Rasuvo can be used as subcutaneous injection of methotrexate.

The generics of Rasuvo are possible to be released after 01 June, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231 MEDEXUS Concentrated methotrexate solutions
Jun, 2029

(6 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic